292 related articles for article (PubMed ID: 30999260)
1. Long-term safety and efficacy following conversion to eslicarbazepine acetate monotherapy in adults with focal seizures.
Chung S; Sinha SR; Shah A; Stern JM; Cheng H; Jung J; Grinnell T; Blum D
Epilepsy Res; 2019 Jul; 153():59-65. PubMed ID: 30999260
[TBL] [Abstract][Full Text] [Related]
2. Tolerability of adjunctive eslicarbazepine acetate according to concomitant lamotrigine or carbamazepine use: A subgroup analysis of three phase III trials in adults with focal (partial-onset) seizures.
Abou-Khalil B; Klein P; Shah A; Ryvlin P; Specchio LM; Gama H; Rocha F; Blum D; Grinnell T; Cheng H; Jung J
Epilepsy Res; 2018 Nov; 147():80-86. PubMed ID: 30278294
[TBL] [Abstract][Full Text] [Related]
3. Associations between seizure severity change and patient characteristics, changes in seizure frequency, and health-related quality of life in patients with focal seizures treated with adjunctive eslicarbazepine acetate: Post hoc analyses of clinical trial results.
Cramer JA; Colman S; Anastassopoulos KP; Grinnell T; Mehta D; Williams GR
Epilepsy Behav; 2020 Nov; 112():107312. PubMed ID: 32801102
[TBL] [Abstract][Full Text] [Related]
4. Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial.
Sperling MR; Abou-Khalil B; Harvey J; Rogin JB; Biraben A; Galimberti CA; Kowacs PA; Hong SB; Cheng H; Blum D; Nunes T; Soares-da-Silva P;
Epilepsia; 2015 Feb; 56(2):244-53. PubMed ID: 25528898
[TBL] [Abstract][Full Text] [Related]
5. Psychiatric and cognitive adverse events: A pooled analysis of three phase III trials of adjunctive eslicarbazepine acetate for partial-onset seizures.
Andermann E; Biton V; Benbadis SR; Shneker B; Shah AK; Carreño M; Trinka E; Ben-Menachem E; Biraben A; Rocha F; Gama H; Cheng H; Blum D;
Epilepsy Behav; 2018 May; 82():119-127. PubMed ID: 29604484
[TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy and safety of eslicarbazepine acetate monotherapy for adults with newly diagnosed focal epilepsy: An open-label extension study.
Trinka E; Rocamora R; Chaves J; Moreira J; Ikedo F; Soares-da-Silva P;
Epilepsia; 2020 Oct; 61(10):2129-2141. PubMed ID: 32944934
[TBL] [Abstract][Full Text] [Related]
7. Safety and Tolerability of Adjunctive Eslicarbazepine Acetate in Pediatric Patients (Aged 4-17 Years) With Focal Seizures.
Mintz M; Pina-Garza JE; Wolf SM; McGoldrick PE; Józwiak S; Grinnell T; Cantu D; Costa R; Moreira J; Li Y; Blum D
J Child Neurol; 2020 Mar; 35(4):265-273. PubMed ID: 31878820
[TBL] [Abstract][Full Text] [Related]
8. Pooled efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: Data from four double-blind placebo-controlled pivotal phase III clinical studies.
Elger C; Koepp M; Trinka E; Villanueva V; Chaves J; Ben-Menachen E; Kowacs PA; Gil-Nagel A; Moreira J; Gama H; Rocha JF; Soares-da-Silva P
CNS Neurosci Ther; 2017 Dec; 23(12):961-972. PubMed ID: 29030894
[TBL] [Abstract][Full Text] [Related]
9. Adjunctive eslicarbazepine acetate: A pooled analysis of three phase III trials.
Biton V; Rogin JB; Krauss G; Abou-Khalil B; Rocha JF; Moreira J; Gama H; Trinka E; Elger CE; Cheng H; Grinnell T; Blum D;
Epilepsy Behav; 2017 Jul; 72():127-134. PubMed ID: 28575761
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a historical-control phase III study.
Jacobson MP; Pazdera L; Bhatia P; Grinnell T; Cheng H; Blum D;
BMC Neurol; 2015 Mar; 15():46. PubMed ID: 25880756
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a randomized historical-control phase III study based in North America.
Sperling MR; Harvey J; Grinnell T; Cheng H; Blum D;
Epilepsia; 2015 Apr; 56(4):546-55. PubMed ID: 25689448
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of eslicarbazepine acetate as adjunctive therapy for refractory focal-onset seizures in children: A double-blind, randomized, placebo-controlled, parallel-group, multicenter, phase-III clinical trial.
Kirkham F; Auvin S; Moreira J; Gama H; Falcão AC; Rocha JF; Soares-da-Silva P
Epilepsy Behav; 2020 Apr; 105():106962. PubMed ID: 32151803
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety and efficacy of eslicarbazepine acetate as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy: results of a 1-year open-label extension study.
Hufnagel A; Ben-Menachem E; Gabbai AA; Falcão A; Almeida L; Soares-da-Silva P
Epilepsy Res; 2013 Feb; 103(2-3):262-9. PubMed ID: 22871333
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of eslicarbazepine acetate monotherapy for partial-onset seizures: Experience from a multicenter, observational study.
Toledano R; Jovel CE; Jiménez-Huete A; Bayarri PG; Campos D; Gomariz EL; Giráldez BG; García-Morales I; Falip M; Agredano PM; Palao S; Prior MJAA; Pascual MRQ; Navacerrada FJ; González FJL; Ojeda J; Sáez AA; Bermejo PE; Gil-Nagel A
Epilepsy Behav; 2017 Aug; 73():173-179. PubMed ID: 28641170
[TBL] [Abstract][Full Text] [Related]
15. Long-term effects of adjunctive eslicarbazepine acetate in adult Asian patients with refractory focal seizures: Post hoc analysis of a phase III trial.
Lee SK; Lee SA; Hong SB; Cho YW; Castilla-Fernández G; Fonseca MM; Moreira J; Gama H; Holenz J
Clin Transl Sci; 2024 May; 17(5):e13802. PubMed ID: 38787305
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of eslicarbazepine acetate as a first or later adjunctive therapy in patients with focal seizures.
Hixson J; Gidal B; Pikalov A; Zhang Y; Mehta D; Blum D; Cantu D; Grinnell T;
Epilepsy Res; 2021 Mar; 171():106561. PubMed ID: 33556737
[TBL] [Abstract][Full Text] [Related]
17. Effects of adjunctive eslicarbazepine acetate on neurocognitive functioning in children with refractory focal-onset seizures.
Jóźwiak S; Veggiotti P; Moreira J; Gama H; Rocha F; Soares-da-Silva P
Epilepsy Behav; 2018 Apr; 81():1-11. PubMed ID: 29454255
[TBL] [Abstract][Full Text] [Related]
18. Time to baseline seizure count in patients with focal seizures receiving adjunctive eslicarbazepine acetate in a phase IV clinical trial.
Aboumatar S; Krishnaiengar SR; Cantu D; Zhang Y; Grinnell T
Clin Neurol Neurosurg; 2023 Feb; 225():107552. PubMed ID: 36657359
[TBL] [Abstract][Full Text] [Related]
19. Comparative analysis of the safety and tolerability of eslicarbazepine acetate in older (≥60 years) and younger (18-59 years) adults.
Andermann E; Rosenfeld W; Penovich P; Rogin J; Cendes F; Carreño M; Ramsay RE; Ben-Menachem E; Gama H; Rocha F; Soares-da-Silva P; Tosiello R; Blum D; Grinnell T
Epilepsy Res; 2021 Jan; 169():106478. PubMed ID: 33338829
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes of eslicarbazepine acetate monotherapy for focal-onset seizures: A multicenter audit.
Giráldez BG; Garamendi-Ruiz I; Zurita J; García A; Querol R; Campos D; Cabeza-Alvarez C; Serrano P; López-González FJ; Molins A; Serratosa JM
Acta Neurol Scand; 2019 Dec; 140(6):422-428. PubMed ID: 31498422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]